阿替普酶50mg静脉溶栓治疗急性心肌梗死的疗效观察

Clinical Observation on Intravenous Thrombolytic Therapy with Alteplase 50 mg in the Treatment of Patients with Acute Myocardial Infarction

目的:观察阿替普酶50 mg静脉溶栓治疗急性心肌梗死的效果。方法:150例急性心肌梗死患者随机分为治疗组80例和对照组70例,治疗组给予阿替普酶50 mg、对照组给予尿激酶150万U,静脉溶栓治疗,比较两组治疗效果。结果:两组冠状动脉溶通率,治疗组88.8%,对照组60.0%,两组比较差异有统计学意义(P﹤0.05)。结论:阿替普酶静脉溶栓治疗急性心肌梗死效果明显,溶通率高,是临床上治疗急性心肌梗死的有效药物。

Objective： To explore the curative effect of intravenous thrombolytic therapy with Aheplase 50mg in the treatment of acute myocardial infarction. Methods ：150 patients with AM1 were randomly divided into two groups, treatment group（80 cases） and control group （70 cases ）. 50 mg Aheplase was used in treatment group and 1500000U intravenous thrombolytic therapy of UK （ urokinase ） was given in control group. The curative effect of the two groups were observed. Results：The deoppilation rate of coronary artery was respectively 88.8% in treatment group and 60.0% in control group. There was the significant statistical difference between the two groups in the comparison of curative effect （ P 〈 0.05 ）. Conclusion： Intravenous thrombolytic therapy with Aheplase is superior to UK （ urokinase ）, which is one of the safe and effective methods with good curative effect and high deoppilation in the treatment of AMI.